Developing circular-DNA blood tests for earlier cancer detection and monitoring
Cancer can develop before symptoms trigger diagnosis, narrowing the opportunity for early treatment. Tissue biopsies are invasive and difficult to repeat, while tumors can change during therapy. Clinicians need accessible ways to detect disease signals and track how cancer evolves over time.
Cleomics is developing blood tests that analyze circular DNA to detect cancer earlier and monitor treatment. Its approach aims to give oncology teams repeatable information about tumor biology from a routine blood sample, supporting more timely decisions.
What stands out about Cleomics
Cleomics joined Nubbo’s 12-month incubation programme in spring 2026 and is also incubated at the University of Perpignan’s UPVD IN CUBE.
Co-founder Philippe Outrebon co-founded veterinary diagnostics company DIAG4ZOO in 2017 and previously founded IT businesses.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.